Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now
Acorda has lost its last-ditch attempt to retain control of the cash cow it badly needed to sustain the company. The Supreme Court has refused to hear its argument against a lower court ruling that opened the gate to knockoffs of its multiple sclerosis drug Ampyra.
Acorda has been gearing for this day for more than 2 years, getting a delayed approval of Inbrija — an inhalation powder of levodopa — late last year, which company execs hope will replace Ampyra as the main revenue stream dwindles. But in Q2 they gained only $3 million in sales from the new drug — well below consensus — while continuing to do much better than expected on the fading franchise.
There wasn’t much hope for a last-minute win here, and Acorda’s battered shares $ACOR were up 5% in Monday morning trading.